# Harrow, Inc. (HROW): Analyst Ratings Suggest 81% Upside Potential in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/harrow-inc-hrow-analyst-ratings-suggest-81-upside-potential-in-the-healthcare-sector/4121206604
- Published: 2025-07-08T10:49:41+01:00
- Author: Madison Wilson

Harrow, Inc. (NASDAQ: HROW) stands out as a compelling opportunity within the healthcare
sector, specifically in the niche of ophthalmic pharmaceuticals. With its roots 
dating back to 1998 and a recent name change from Harrow Health, Inc. in September
2023, the company is based in Nashville, Tennessee, and specializes in the development
and commercialization of eye care pharmaceutical products. Harrow’s portfolio features
a diverse range of ophthalmic solutions including IHEEZO, MAXITROL, and VIGAMOX,
to name a few, which cater to various ophthalmic conditions.

Despite a current stock price of $31.36, Harrow presents an intriguing investment
case, bolstered by a market capitalization of $1.15 billion. The stock has experienced
a modest dip recently, down by 0.39 points or 0.01%, but this should not overshadow
its broader market performance. Over the last 52 weeks, Harrow’s stock has fluctuated
between $21.98 and $57.48, indicating potential volatility but also significant 
upside potential.

Harrow’s valuation metrics reveal a forward P/E of 13.34, suggesting expectations
of earnings growth moving forward. However, traditional valuation metrics such as
trailing P/E and PEG ratio are not available, which may indicate the company is 
in a transitional phase with earnings not yet solidified.

On the performance front, Harrow has demonstrated robust revenue growth of 38.30%,
a testament to its expanding market reach and product acceptance. However, the company
is currently operating at a loss with an EPS of -0.61 and a negative return on equity
of -37.31%. Free cash flow is also in the negative territory at -$26.88 million,
highlighting the need for investors to weigh growth prospects against current financial
health.

Dividend-seeking investors might find Harrow less appealing, as it does not offer
a dividend yield, focusing instead on reinvesting earnings to drive growth.

Analyst sentiment is decidedly bullish, with 7 buy ratings and no hold or sell recommendations.
The average target price is set at $56.89, suggesting a remarkable 81.40% potential
upside from the current price. This optimism is reflected in the technical indicators:
the stock’s 50-day moving average is $28.17, while the 200-day moving average stands
at $34.33. The relative strength index (RSI) is at 65.87, nearing the overbought
territory, which could imply further upward momentum.

Investors considering Harrow should be aware of the inherent risks, given its current
financial performance metrics. However, with a strong product lineup and a focus
on the rapidly growing ophthalmic pharmaceutical market, Harrow appears well-positioned
for future growth. As always, potential investors should conduct further research
and consider their risk tolerance before making investment decisions.

Share on: